搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
23 小时
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular ...
Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...
FierceBiotech
21 小时
Abbott advances clinical studies in pulsed field ablation, collects mapping clearance from FDA
Abbott has received an FDA clearance for the latest version of its sensor-laden catheter used to map out the electrical ...
FierceBiotech
23 小时
Bruker spools up spatial biology division from NanoString, Canopy assets
Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years. | Bruker ...
FierceBiotech
1 天
Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data
In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...
FierceBiotech
1 天
Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track
In order to focus its resources on the phase 1 program, dubbed TIDAL-01, the company has today announced a reduction in staff ...
FierceBiotech
1 天
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen
Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. | ...
FierceBiotech
1 天
Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4
Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...
FierceBiotech
1 天
'Impossible' FDA adcomm ends in favor of Stealth’s ultra-rare disease med
Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...
FierceBiotech
1 天
Sanofi flunks midphase multiple sclerosis study, dealing another blow to Denali pact
Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...
FierceBiotech
2 天
Novo Holdings-backed Booster takes off with protein degraders aimed at neurodegeneration
Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...
FierceBiotech
1 天
Chutes & Ladders—Lilly goes all-in on AI with new exec position
Eli Lilly is ramping up its efforts to incorporate AI across its business by appointing Thomas Fuchs to the new role of chief ...
FierceBiotech
2 天
Ono links with LigaChem to bag preclinical ADC in $700M biobuck deal
Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing | Ono ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈